Simba gill biography

Earlier, he was global marketing director at Boehringer Mannheim, acquired in 1997 by Roche.
Simba Gill is Chairman at Serina Therapeutics Inc. See Simba Gill's compensation, career history, education, & memberships.
Gill is a true champion of Evelo's potential to help billions across the world and has believed in the company's unconventional drug discovery approach.

•

Creating the Future of Microbiome-Based Therapies: Simba Gill on The Long Run

Today’s guest on The Long Run is Simba Gill.

Simba is the CEO of Cambridge, Mass.-based Evelo Biosciences.

Simba Gill, CEO, Evelo Biosciences

Evelo is part of a new generation of biotech companies seeking to make medicines based on new understanding of the microbiome. The science here is fascinating. Evelo’s drug candidates are biologics designed to be taken orally, to act directly in the gut, and to have therapeutic effects throughout the body.

In this conversation, Simba describes what the key scientific discoveries were that inspired the founding of Evelo, and how the company created a strategy for therapeutic interventions (which is no obvious thing). Evelo is in the clinical development stages with drug candidates for chronic inflammatory diseases like psoriasis and for cancer. Based on some of its clinical observations, there’s even a rationale for testing one of its candidates for COVID-19 – clinical studies are ongoing.

Simba grew up in the UK, and got his scientific training as an immuno

•

Simba Gill

Maxygen, Inc.

Miscellaneous Commercial ServicesCommercial Services

Maxygen, Inc. is a biotechnology company. It is focused on the potential further development of its MAXY-G34 product, a next-generation pegylated, granulocyte colony stimulating factor, G-CSF, for the treatment of chemotherapy induced neutropenia and acute radiation syndrome. G-CSF is a natural protein that functions by stimulating the body's bone marrow to produce more white blood cells. The company was founded on May 7, 1996 and is headquartered in San Mateo, CA.

Commercial Services

TPG Growth LLC

Investment ManagersFinance

TPG Growth LLC is a Venture Capital firm, a subsidiary of TPG Capital Advisors LLC founded in 2000 by William E. McGlashan and Michael Guthrie. The firm is headquartered in San Francisco, United States with additional office in London, United Kingdom.

Finance

moksha8 Pharmaceuticals, Inc.

Pharmaceuticals: MajorHealth Technology

moksha8 Pharmaceuticals, Inc. ope

•

Simba Gill

Simba Gill, PhD, is president and chief executive officer of Evelo Biosciences, a Flagship VentureLabs company leading the development of monoclonal microbials, a new modality of medicine for the treatment of cancer and autoimmune and inflammatory diseases.

He is also a senior partner at Flagship Pioneering, where he provides strategic counsel and support to the firm’s portfolio companies. Prior to his roles at Evelo and Flagship, Simba was a partner at TPG, a major private equity investor, where he focused on global healthcare and biotech investments. He has also held leadership roles at Roche/Boehringer Manheim.

Simba has a long track record of identifying new technologies and geographies for high-growth business opportunities. He has founded and held leading roles in multiple pioneering companies in the fields of antibodies, stem cells, directed molecular evolution, gene therapy, and immunodiagnostics. Four of these companies have gone public and three were acquired through strategic trade sales.

Simba holds his MBA from INSEAD and received his PhD from King’s C